<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640508</url>
  </required_header>
  <id_info>
    <org_study_id>CTMS 15-2139</org_study_id>
    <secondary_id>HSC20150891H</secondary_id>
    <nct_id>NCT02640508</nct_id>
  </id_info>
  <brief_title>Eribulin and Lenvatinib in Advanced Solid Tumors</brief_title>
  <official_title>Phase II Trial of Eribulin and Lenvatinib in Advanced Solid Tumors (CTMS# 15-2139)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia G. Kaklamani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose of this study is to determine the overall response rate, efficacy and
      safety of the combination of eribulin and Lenvatinib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II clinical trial of the combination of eribulin, and Lenvatinib. A cycle
      will be defined as 21 days. Eribulin will be given on days 1 and 8 of each cycle. Lenvatinib
      will be given daily during each cycle.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate of lenvatinib and eribulin</measure>
    <time_frame>The overall response rate will be assessed after two cycles of therapy (1 cycle = 3 weeks) until the date of first documentation of disease progression or death (whichever occurs first) over an average of 18 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lenvatinib and eribulin toxicities will be graded using NCI CTCAE version 4.03</measure>
    <time_frame>Safety will be evaluated from the time of registration until 30 days after last dose of treatment, resolution of the related AE or death.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Cancer</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Combination Eribulin and lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eribulin will be given on days 1 and 8. Lenvatinib will be given daily in each 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin</intervention_name>
    <description>Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.</description>
    <arm_group_label>Combination Eribulin and lenvatinib</arm_group_label>
    <other_name>Halaven</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Will be taken orally at 20-24 mg daily in each 21 day cycle.</description>
    <arm_group_label>Combination Eribulin and lenvatinib</arm_group_label>
    <other_name>Lenvima</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage IV breast cancer, stage IV NSCLC (Non-Small Cell Lung Cancer) (, stage IV
             sarcoma

          -  ECOG (Eastern Cooperative Oncology Group) PS (Performance Status) 0-2

          -  Measurable disease

          -  No more than 4 prior chemotherapeutic regimens for metastatic disease

          -  Patients must be &gt;/= 18 years.

          -  Patients may not have received eribulin or lenvatinib previously

          -  Patients must have a life expectancy of greater than 12 weeks.

          -  Patients may have had a prior diagnosis of cancer if it has been &gt; 5 years since their
             last treatment and are considered free of disease.

          -  Patients must have normal organ and marrow function as defined below:

        Leukocytes ≥ 3,000/uL Absolute neutrophil count ≥ 1,500/uL Platelets ≥ 100,000/uL Child
        Pugh score ≤ 10 Patients must be able to swallow and retain oral medication. All patients
        must have given signed, informed consent prior to registration on study.

        Exclusion Criteria:

          -  Women who are pregnant or lactating are not eligible for study treatment.

          -  Patients who are undergoing concomitant radiotherapy are NOT eligible for
             participation.

          -  Patients who are receiving any other investigational agents or concurrent anticancer
             therapy are NOT eligible for participation. Previous systemic treatment and/or
             radiation therapy is allowed with a 14 day washout period prior to registration.

          -  Lesions that have been radiated previously cannot be considered target lesions

          -  Prior treatment related side effects must have resolved to &lt; Grade 2 severity per
             Common Terminology Criteria for Adverse Events (CTCAE version 4.03), except alopecia
             and infertility.

          -  Patients who are taking any herbal (alternative) medicines are NOT eligible for
             participation. Patients must be off any such medications by the time of registration.

          -  Patients with known brain metastases are NOT eligible for participation unless the
             brain metastases are treated (either with surgical excision, stereotactic radiosurgery
             or radiotherapy) and have been stable for at least 4 wks per MR performed, the patient
             is asymptomatic and has discontinued corticosteroids if taken for that purpose.

          -  Patients with any of the following conditions or complications are NOT eligible for
             participation:

               1. GI tract disease resulting in an inability to take oral medication

               2. Malabsorption syndrome

               3. Require IV alimentation

               4. History of prior surgical procedures affecting absorption

               5. Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).

               6. Hypersensitivity of any of the components of eribulin or lenvatinib

               7. History of significant neurological ( no neuropathy more than grade 2) or
                  psychiatric disorders

               8. Significant non neoplastic liver disease (Cirrhosis, active chronic hepatitis)

               9. Immunocompromised subjects, including patients with human immunodeficiency virus

              10. Significant non neoplastic renal disease

              11. Active infection requiring systemic therapy.

              12. Significant cardiovascular impairment: history of congestive heart failure
                  greater than New York Heart Association (NYHA) Class II, uncontrolled arterial
                  hypertension, unstable angina, myocardial infarction or stroke within 6 months of
                  the first dose of study drug; or cardiac arrhythmia requiring medical treatment

              13. Prolongation of QTc interval to more than 480 milliseconds when electrolyte
                  balance is normal

              14. Major surgery within 4 weeks prior to first dose of the study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia Kaklamani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Epp Goodwin</last_name>
    <phone>210-450-1000</phone>
    <email>ctrcreferral@uthscsa.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center University of Texas Health Science Center San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Epp Goodwin</last_name>
      <phone>210-450-5798</phone>
      <email>CTRCReferral@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Virgina Kaklamani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2015</study_first_submitted>
  <study_first_submitted_qc>December 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Virginia G. Kaklamani</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

